SML2312
Tipranavir
≥98% (HPLC)
别名:
5-trifluoromethyl-N-[3(R)-[1-[5,6-dihydro-4-hydroxy-2-oxo-6(R)-(2-phenethyl)-6(R)-n-propyl-2H-pyran-3-yl]propyl]phenyl]-2-pyridinesulfonamide, N-[3-[(1R)-1-[(6R)-5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)-pyridinesulfonamide, PNU 140690, PNU-140690, TPV
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C31H33F3N2O5S
化学文摘社编号:
分子量:
602.66
NACRES:
NA.77
UNSPSC Code:
51111800
MDL number:
产品名称
Tipranavir, ≥98% (HPLC)
InChI
1S/C31H33F3N2O5S/c1-3-16-30(17-15-21-9-6-5-7-10-21)19-26(37)28(29(38)41-30)25(4-2)22-11-8-12-24(18-22)36-42(39,40)27-14-13-23(20-35-27)31(32,33)34/h5-14,18,20,25,36-37H,3-4,15-17,19H2,1-2H3/t25-,30-/m1/s1
InChI key
SUJUHGSWHZTSEU-FYBSXPHGSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
Biochem/physiol Actions
HIV protease inhibitor that is highly potent against a variety of HIV strains and isolates in several cell culture systems
Tipranavir is a HIV protease inhibitor that is highly potent against a variety of HIV strains and isolates in several cell culture systems. Tipranavir inhibits the replication of viruses that are resistant to other protease inhibitors.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
S M Poppe et al.
Antimicrobial agents and chemotherapy, 41(5), 1058-1063 (1997-05-01)
PNU-140690 is a member of a new class of nonpeptidic human immunodeficiency virus (HIV) protease inhibitors (sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones) discovered by structure-based design. PNU-140690 has excellent potency against a variety of HIV type 1 (HIV-1) laboratory strains and clinical isolates, including
Manabu Aoki et al.
Journal of virology, 86(24), 13384-13396 (2012-09-28)
Tipranavir (TPV), a protease inhibitor (PI) inhibiting the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-PI-resistant HIV-1 isolates. When a mixture of 11 multi-PI-resistant (but TPV-sensitive) clinical isolates (HIV(11MIX)), which included HIV(B) and HIV(C), was selected
Soo-Yon Rhee et al.
Antimicrobial agents and chemotherapy, 54(10), 4253-4261 (2010-07-28)
The effects of many protease inhibitor (PI)-selected mutations on the susceptibility to individual PIs are unknown. We analyzed in vitro susceptibility test results on 2,725 HIV-1 protease isolates. More than 2,400 isolates had been tested for susceptibility to fosamprenavir, indinavir
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持